# Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Source: https://onco.cc/trials/nct06731894/  
OnCo record `nct06731894` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dronabinol in Breast cancer, run by City of Hope Medical Center, now recruiting.

## Summary

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors is a phase 2 interventional study registered as NCT06731894 by City of Hope Medical Center, with 120 participants planned, started 2025-10-03 and due to reach its primary completion in 2028-01-07. Interventions recorded: Biospecimen Collection, Cannabidiol, Dronabinol, Placebo Administration, Survey Administration. Conditions recorded: Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma.

Linked to the drug Dronabinol because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06731894
- Phase: 2
- Setting: A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy
- Sponsor: City of Hope Medical Center
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT06731894: https://clinicaltrials.gov/study/NCT06731894

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Dronabinol](https://onco.cc/drugs/dronabinol/)

---
JSON: https://onco.cc/api/v1/entities/nct06731894.json